GRB17

antibody from Invitrogen Antibodies

Targeting: GZMB CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT

Provider product page for GRB17

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [19]
Comments [0]
Validations
Other assay [5]

Submit

Product number: GRB17 - Provider product page
Provider: Invitrogen Antibodies
Product name: Granzyme B Monoclonal Antibody (GB11), PE-Texas Red
Antibody type: Monoclonal
Antigen: Other
Description: According to the literature this antibody recognizes the serine protease, granzyme B1. This enzyme is involved in apoptotic cell death. Granzyme B, as well as other enzymes contained in lytic granules, is released primarily by cytotoxic T lymphocytes (CTLs). In addition to immunostaining for flow cytometry, the GB11 mAb has been shown to be useful as an ELISA capture antibody.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: GB11
Vial size: 500 µL
Storage: 4° C

GZMB protein structure - GRB17 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 WAS patient spleen NK cells have altered receptor expression. ( A ) CD56 expression on healthy PBMCs, healthy splenocytes, and WAS patient splenocytes, plotted against CD3 in the plots and as MFI in the histograms. ( B ) CD69 and DNAM-1 surface expression, and Granzyme B and Perforin intracellular content in healthy PBMCs, healthy splenocytes, and WAS patient splenocytes. ( C ) Degranulation, as measured by CD107a surface expression and IFNgamma production in healthy PBMCs, healthy splenocytes, and WAS patient splenocytes shown in contour plots ( left ) and a bar graph ( right ). ( D - F ) Expression analysis and survival of neuroblastoma patients in the R2 database, (R2: Genomics Analysis and Visualization Platform; http://r2.amc.nl ). n = 498 ( D ) Correlation of WASp and IL-2 expression in neuroblastoma patients. Each patient is represented by circles for WASp expression (black circle; left Y-axis) and IL-2 expression (grey circle; right Y-axis). ( E , F ) Survival curves of ( E ) neuroblastoma patients and ( F ) diffuse large B cell lymphoma patients with high WASp expression (blue) and low WASp expression (red). Survival curves of ( E ) neuroblastoma patients and ( F ) diffuse large B cell lymphoma patients with high IL-2 expression (blue) and low IL-2 expression (red).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure S7 Baricitinib treatment did not affect the immune T cell responses in SARS-CoV-2-infected RMs, related to Figure 6 (A-C) Frequency of circulating CD4+ T cells spontaneously (without stimulation) producing pro-inflammatory Th17 related cytokines (A) IL-17 + , (B) IL-17 + IL-21 + , (C) IL-17 + IL- 22 + at necropsy (days 10-11 after infection) in baricitinib (blue) and untreated (red) SARS-CoV-2 infected RMs. (D) Representative flow cytometry staining of IFNgamma, TNFalpha, IL-2, IL-4 and IL-17a in CD4 + and CD8 + T cells of a SARS-CoV-2 infected RM following stimulation with SARS-CoV-2 S peptide pool. IFNgamma, Unstimulated background values were subtracted from S peptide stimulated values to determine T cell cytokine. (E and F) IFNgamma, TNFalpha, IL-2, IL-4 and IL-17a frequency levels in (E) CD4 + and (F) CD8 + T cells following stimulation with SARS-CoV-2 S peptide pool. (G-L) IFNgamma, TNFalpha, IL-2, IL-4 and IL-17a frequency levels in (G) CD4 + and (H) CD8 + T cells following stimulation with PMA/Ionomycin. Values from unstimulated controls were subtracted in all cases. Granzyme B and PD-1 levels in (I and J) blood and (K and L) BAL memory CD8 + T cells measured by flow cytometry. Each symbol represents individual animals. Thick lines represent the average of the baricitinib treated (blue line), and untreated groups (red line). Bars represent the average of the treated and untreated groups. Statistical analysis was performed using a non-parametric Mann-Whitney Tes

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Proof-in-concept that inhaled IL-15 drives peripheral NK and CD8 + T cell activation and TIGIT upregulation in dogs with metastatic osteosarcoma. (A) Schema for our first-in-dog clinical trial of inhaled IL-15 in dogs with naturally occurring metastatic osteosarcoma. (B) Representative flow cytometry showing peripheral blood CD45 + , lymphocytes, CD3, CD3 - NKp46 + NK, and CD3 + CD8 + T cell populations. (C-D) Inhaled IL-15 stimulates peripheral cytotoxic lymphocytes in vivo leading to upregulation of granzyme B and Ki67 by flow cytometry analysis. (E-F) Fold change in granzyme B expression significantly increased on NK cells (p=0.01) and fold change in Ki67 expression significantly increased on T cells (p=0.03). (G) RNA sequencing analysis of CD5-depleted NK cells from three dogs on-trial showing TIGIT upregulation in 2/3 patients. Mean+-SEM. P values determined using paired Student's t-test. Fold change comparison using Pre Tx value of 1. IL-15, interleukin 15; NK, natural killer; On Tx, on treatment; Pre Tx, pretreatment.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 FTY720 treatment in the first weeks of ART retains cytolytic cells but does not enhance their functionality in the LN. a Frequency of CD4+ T cells, b CD8+ T cells, and ( c ) ratio of CD4+/CD8+ T cells in lymph node (LN) mononuclear cells at baseline (week -1) and at 8 weeks of treatment in early FTY720 ( n = 8 RMs) or control (n = 14 RMs) SIV-infected RMs. d Frequency of LN perforin+ (Perf+), e granzyme B (GrB+), and ( f ) Perf+GrB+ CD8+ T cells at baseline (week -1) and at 8 weeks in early FTY720 (red) or control (black) SIV-infected RMs. g Fold reduction between week -1 and week 8 of Perf+GrB+ CD8+ T cells, and ( h ) frequency of LN CD8+ T cells expressing CXCR5 at baseline (week -1) and at 8 weeks in early FTY720 ( n = 8 RMs) and control ( n = 14 RMs) SIV-infected RMs. i Representative flow cytometry staining of P185 mastocytoma target cells (TFL4+ cells) expressing active caspase-3 when cultured alone or co-cultured with different ratios of effector CD8+ T cells derived from LN. j Frequency of target cells expressing active caspase 3 following co-culture with CD8+ T cells derived from LN at week 8 from early FTY720 ( n = 8 RMs) or control ( n = 7 RMs) SIV-infected RMs. k Representative flow cytometry staining of CD56-CD16+NK+ cells in LN at week -1 and 8 from early FTY720 (top) or control SIV-infected RMs (bottom). l Frequency of CD56-CD16+ NK cells and ( m ) CD16 geometric mean fluorescence intensity (geomean) in NK cells derived from LN at week -1 and 8 from earl

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 NDV induces increased immune infiltration and delay of tumor growth in treated and distant tumors Animals bearing bilateral flank MB49 bladder tumors were treated with 3 injections of NDV administered every other day into right tumor. ( A - D ) The tumors were collected 3 days after last treatment and analyzed by flow cytometry. (A) Representative flow cytometry plots showing proportion of CD4+ and CD8+ cells (% of all live single cells) (top) and proportion of Foxp3- and FoxP3+ CD4 cells (% of all CD4) (bottom) in tumors treated with PBS (left) or NDV (right). (B) T cell infiltration in the treated tumors and expression of activation (ICOS), lytic (GrB), and proliferation (Ki-67) markers by the CD8 and Tcon lymphocytes from treated tumors. (C) Representative flow cytometry plots showing proportion of CD4+ and CD8+ cells (%of all live single cells) (top) and proportion of Foxp3- and FoxP3+ CD4 cells (%of all CD4) (bottom) in distant tumors of mice treated with PBS (left) or NDV (right). (D) T cell infiltration in the distant tumors and expression of activation (ICOS), lytic (Granzyme B), and proliferation (Ki-67) markers by the CD8 and Tcon lymphocytes from distant tumors. ( E - G ) Animals bearing bilateral flank MB49 bladder tumors were treated with 4 injections of NDV administered every other day into right tumor. (E) Treatment schema. (F) Growth of treated and distant tumors and mean tumor growth curves (+- SEM) compared at day 21 post treatment. (G) Overall